End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
223 CNY | +1.98% | +4.44% | +6.07% |
Apr. 24 | Imeik Technology Development Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 20 | Imeik Technology Development's Profit Rises 47% on Higher Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With a 2024 P/E ratio at 26.64 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.07% | 9.27B | C | ||
+10.11% | 126B | A- | ||
-6.02% | 11.33B | A- | ||
+37.46% | 5.5B | B+ | ||
+8.53% | 3.45B | C- | ||
-8.69% | 2.81B | B- | ||
-6.38% | 2.08B | - | ||
-10.91% | 2.09B | - | - | |
-23.21% | 1.78B | - | C- | |
-9.17% | 1.14B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300896 Stock
- Ratings Imeik Technology Development Co.,Ltd.